Maria I. Natalicchio
Foggia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement.
Journal: Tumori
Published: September 29, 2025
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience.
Journal: European urology oncology
Published: February 18, 2025
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 14, 2024
An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients.
Journal: Bioengineering (Basel, Switzerland)
Published: June 05, 2023
Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing.
Journal: Cancers
Published: August 10, 2021
A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
Journal: Acta bio-medica : Atenei Parmensis
Published: April 27, 2021
Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study.
Journal: Diagnostics (Basel, Switzerland)
Published: February 17, 2020
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
Journal: Medicine
Published: May 25, 2019
Comparative Gene Expression Profiling of Tobacco-Associated HPV-Positive versus Negative Oral Squamous Carcinoma Cell Lines.
Journal: International journal of medical sciences
Published: March 22, 2019
BRCAmut and "founder effect": a prospective study in a single academic institution.
Journal: Oncotarget
Published: January 24, 2018
Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.
Journal: Medical oncology (Northwood, London, England)
Published: November 22, 2017
Last Updated: 09/26/2026